Effect of Ulva fasciata Delile and Turbinaria decurrens Bory ethyl acetate extracts feeding on the growth rate of Adenocarcinoma mammae on C3H mice

Breast cancer is the second mostly found disease after cervix cancer to Indonesian woman. Research on the effect of Ulva fasciata Delile and Turbinaria decurrens Bory ethyl acetate extracts feeding on the growth rate of Adenocarcinoma mammae on cell proliferation C3H mice has been conducted. Thirty...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Jurnal pascapanen dan bioteknologi kelautan dan perikanan 2011-01, Vol.6 (1), p.57-68
Hauptverfasser: Wikanta, T, Handayani, V F, Rahayu, L, Pratitis, A, Wuyung, P E
Format: Artikel
Sprache:ind
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Breast cancer is the second mostly found disease after cervix cancer to Indonesian woman. Research on the effect of Ulva fasciata Delile and Turbinaria decurrens Bory ethyl acetate extracts feeding on the growth rate of Adenocarcinoma mammae on cell proliferation C3H mice has been conducted. Thirty experimental mice were divided into 6 treatment groups. i.e. K-I, negative control; K-II, solvent control; K-III, given U. fasciata ethyl acetate extract dose of 41.32 mg/20 g BW (body weight); K-IV, given U. fasciata ethyl acetate extract dose of 82.64 mg/20 g BW; K-V given T. decurrens ethyl acetate extract dose of 24.29 mg/20 g BW; and K-VI, given T. decurrens ethyl acetate extract dose 48.59 mg/20 g BW. All treatments were given during 21 days. The mice body weight and tumor volumes were measured and collected subsequently at every two days. Tumor doubling time was calculated at the end of research. Results showed that there was a highly tumor growth inhibition on the K-IV shown by the high doubling time value. Tumor growth inhibition decreased according to sequence as follows: K-IV (U. fasciata dose of 82.64 mg/20 g BW), K-V (U. fasciata dose of 24.29 mg/20 g BW), K-VI (U. fasciata dose of 48.59 mg/20 g BW) which equal to K-II (solvent control), K-III (U. fasciata dose of 41.32 mg/20 g BW), K-I (negative control).
ISSN:1907-9133
2406-9264